예측 바이오마커 시장 규모, 점유율, 동향 분석 리포트 : 적응증별, 기술별, 지역별, 부문 예측(2025-2030년)

Predictive Biomarkers Market Summary

The global predictive biomarkers market size was estimated at USD 24.30 billion in 2024 and is projected to reach USD 63.54 billion by 2030, growing at a CAGR of 18.02% from 2025 to 2030. The market is experiencing significant growth driven by several factors such as advancements in genomics and precision medicines, increased investment in research and development and rising demand for early detection and personalized treatments.

Research and development (R&D) is a major driver of growth in the predictive biomarkers market, fueling innovation and the discovery of new biomarker candidates. Genomics and precision medicine are at the forefront of medical technology, offering the potential for more targeted and effective treatments. Predictive biomarkers for the effects of interventions can reflect an individual's biological constituents ("host characteristics") or traits associated with the disease process or other medical conditions. The NHS and the government are making significant investments in these technologies, including the launch of the NHS Genomic Medicine Service. This service is dedicated to advancements in genomics to benefit patients by implementing genome sequencing, providing molecular diagnostics and genetic testing for cancer patients, and enhancing data integration to facilitate more effective treatments. Moreover, expertise in technology and data analytics with proficiency in developing new sequencing technologies, is

achieved through collaborations that drive innovation and advance precision medicine for instance, in April 2025, Illumnia collaborated with Tempus AI to accelerate adoption of next generation sequencing tests for patients.

The growing investment in research and development (R&D) is a key driver of the predictive biomarkers market. Pharmaceutical companies, biotech firms, and academic institutions are dedicating significant resources to discovering new biomarkers and advancing diagnostic technologies. One prominent application for biomarker identification is next-generation sequencing (NGS), which can rapidly detect millions of DNA copies within a gene. This technology enables comprehensive profiling of multiple genes and mutations in a short amount of time. For example, Illumina's NovaSeq X platform offers high-throughput sequencing for analyzing large sequences of data and diagnose the condition of disease. The increasing funding and collaborative efforts in biomarker discovery lead to the development of more effective and accurate predictive tests. This, in turn, is accelerating the growth of the predictive biomarkers market, supporting the next generation of healthcare innovations.

There is an increasing demand for early disease detection and personalized treatments, which is one of the key driver in predictive biomarkers market. Biomarkers provide valuable insights into an individual's health, helping identify diseases in their early stages before symptoms appear. Early detection enables more effective interventions, improving patient outcomes and reducing treatment costs. An important application of predictive biomarkers is in oncology, which demonstrates resistance to treatment that continues to be a leading cause of mortality in breast cancer patients, driving the need for the development of predictive biomarkers.

Innovative approaches, such as omics technologies and artificial intelligence, are being explored to identify highly accurate molecular or imaging biomarkers, with the potential to enhance treatment outcomes. Biomarkers are even gaining popularity incorporation into clinical trials for safety and efficacy tests. Predictive biomarkers may also become a part of these trials tailoring of medicines according to patient needs. As healthcare systems shift toward individualized medicine, predictive biomarkers play a crucial role in optimizing treatment regimens and ensuring the right therapy for each patient.

Global Predictive Biomarkers Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global predictive biomarkers market report on the basis of indication, technology and region.

• Indication Outlook (Revenue, USD Million, 2018 - 2030)
• Cancer
• Cardiovascular Diseases
• Neurological Diseases
• Immunological Diseases
• Others
• Technology Outlook (Revenue, USD Million, 2018 - 2030)
• Diagnostics
• Drug Discovery & Development
• Personalized Medicine
• Disease Risk Assessment
• Others
• Regional Outlook (Revenue in USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
  • 1.2.2. Technology
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Indication outlook
  • 2.2.2. Technology outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Predictive Biomarkers Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Predictive Biomarkers Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Predictive Biomarkers Market: Indication Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Predictive Biomarkers Market: Indication Movement Analysis
• 4.3. Predictive Biomarkers Market Size & Trend Analysis, by indication, 2018 to 2030 (USD Million)
• 4.4. Predictive Biomarkers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Cancer
  • 4.5.1. Cancer Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Cardiovascular Diseases
  • 4.6.1. Cardiovascular Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Neurological Diseases
  • 4.7.1. Neurological Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Immunological Diseases
  • 4.8.1. Immunological Diseases Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Predictive Biomarkers Market: Technology Estimates & Trend Analysis

• 5.1. Technology Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Predictive Biomarkers Market by Technology Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Diagnostics
  • 5.5.1. Diagnostics Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Drug Discovery & Development
  • 5.6.1. Drug Discovery & Development Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Personalized Medicine
  • 5.7.1. Personalized Medicine Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Disease Risk Assessment
  • 5.8.1. Disease Risk Assessment Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Predictive Biomarkers Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. North America: SWOT Analysis
  • 6.5.2. U.S.
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/Reimbursement
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Canada
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/Reimbursement
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Mexico
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/Reimbursement
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Europe
  • 6.6.1. Europe: SWOT Analysis
  • 6.6.2. UK
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/Reimbursement
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. Germany
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/Reimbursement
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. France
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/Reimbursement
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Italy
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/Reimbursement
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Spain
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/Reimbursement
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.7. Norway
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework/Reimbursement
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.8. Sweden
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework/Reimbursement
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.9. Denmark
    • 6.6.9.1. Key country dynamics
    • 6.6.9.2. Regulatory framework/Reimbursement
    • 6.6.9.3. Competitive scenario
    • 6.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Asia Pacific: SWOT Analysis
  • 6.7.2. Japan
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/Reimbursement
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. China
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/Reimbursement
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. India
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/Reimbursement
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.5. Australia
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/Reimbursement
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.6. South Korea
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework/Reimbursement
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.7. Thailand
    • 6.7.7.1. Key country dynamics
    • 6.7.7.2. Regulatory framework/Reimbursement
    • 6.7.7.3. Competitive scenario
    • 6.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Latin America
  • 6.8.1. Latin America: SWOT Analysis
  • 6.8.2. Brazil
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/Reimbursement
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.3. Argentina
    • 6.8.3.1. Key country dynamics
    • 6.8.3.2. Regulatory framework/Reimbursement
    • 6.8.3.3. Competitive scenario
    • 6.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. MEA
  • 6.9.1. MEA: SWOT Analysis
  • 6.9.2. South Africa
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework/Reimbursement
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.3. Saudi Arabia
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework/Reimbursement
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.4. UAE
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework/Reimbursement
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.5. Kuwait
    • 6.9.5.1. Key country dynamics
    • 6.9.5.2. Regulatory framework
    • 6.9.5.3. Competitive scenario
    • 6.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2024
  • 7.3.4. Thermo Fisher Scientific Inc.
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Services benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Qiagen
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Services benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. F. Hoffmann-La Roche Ltd
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Services benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Bio-Rad Laboratories, Inc
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Services benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Agilent Technologies, Inc.
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Services benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Illumina Inc.
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Services benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Merck KGaA
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Services benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Bio-Techne
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Services benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Siemens Healthineers AG
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Services benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. PerkinElmer
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Services benchmarking
    • 7.3.13.4. Strategic initiatives
  • 7.3.14. Myriad Genetics, Inc.
    • 7.3.14.1. Company overview
    • 7.3.14.2. Financial performance
    • 7.3.14.3. Services benchmarking
    • 7.3.14.4. Strategic initiatives
  • 7.3.15. Becton Dickinson
    • 7.3.15.1. Company overview
    • 7.3.15.2. Financial performance
    • 7.3.15.3. Services benchmarking
    • 7.3.15.4. Strategic initiatives
  • 7.3.16. Danaher Corporation
    • 7.3.16.1. Company overview
    • 7.3.16.2. Financial performance
    • 7.3.16.3. Services benchmarking
    • 7.3.16.4. Strategic initiatives
  • 7.3.17. Genomic Health, Inc.
    • 7.3.17.1. Company overview
    • 7.3.17.2. Financial performance
    • 7.3.17.3. Services benchmarking
    • 7.3.17.4. Strategic initiatives
  • 7.3.18. PacBio
    • 7.3.18.1. Company overview
    • 7.3.18.2. Financial performance
    • 7.3.18.3. Services benchmarking
    • 7.3.18.4. Strategic initiatives